Heartstream Ventures into the Wilds of Public Access Defibrillation
Executive Summary
For someone suffering from sudden cardiac arrest, a quick response is the best medicine. But what if it comes form untrained people? Heartstream's AED device could save lives and advocates claim it should be more widely available--in airports, shopping malls, and all places of public gathering. But first the company has to deal with the challenge of making sure the device will be used properly. If they do, they may create the first consumer market for sophisticated medical equipment.
You may also be interested in...
SK Biopharm’s Hefty IPO To Support Novel Anti-Epileptic, Pipeline
SK Biopharmaceuticals is pushing ahead with a planned sizable IPO in South Korea in June as it focuses on successfully commercializing novel anti-epileptic drug Xcopri in the US.
Lupin Optimistic On Albuterol Given COVID-19 Demand
Lupin hopes a surge in demand for albuterol sulphate due to increased off-label use in COVID-19 patients will help its generic version, which is likely to be launched in the first half of FY21. But the Indian firm may recall a batch of metformin after the US FDA recently asked a few companies to retract extended-release versions due to NDMA concerns.
ASCO 2020: Pevonedistat Shows Promise In Higher-Risk MDS
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.
Need a specific report? 1000+ reports available
Buy Reports